cbdMD (YCBD)
XASE:YCBD
Want to see YCBD full AI Analyst Report?
YCBD Stock Chart & Stats
$0.90
$0.03(3.20%)
At close: 4:00 PM EST
$0.90
$0.03(3.20%)
Day’s Range― - ―
52-Week Range$0.47 - $2.56
Previous CloseN/A
Volume6.20K
Average Volume (3M)7.54M
Market Cap
$7.20M
Enterprise Value$6.09M
Total Cash (Recent Filing)$2.64M
Total Debt (Recent Filing)$415.13K
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 19, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding10,497,919
10 Day Avg. Volume860,286
30 Day Avg. Volume7,543,844
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.67
Price to Sales (P/S)0.25
P/FCF Ratio-2.97
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue0.30
Enterprise Value/Gross Profit0.52
Enterprise Value/Ebitda-6.51
Forecast
1Y Price Target
$2.00Price Target Upside122.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.14
Revenue Forecast (FY)$21.20M
Bulls Say, Bears Say
Bulls Say
AcquisitionAnalyst views the acquisition of Bluebird Botanicals as strategic because it adds a premium hemp-derived CBD brand with an established e-commerce customer base and creates cross-selling opportunities across existing product lines.
Operating StabilityAnalyst sees operating stabilization after a company transformation that lowered fixed costs, reduced balance-sheet risk, and refocused the product portfolio toward higher-demand, higher-margin items.
Retail DistributionAnalyst notes expanded distribution and recent product innovation for the Herbal Oasis THC-infused seltzer portfolio should broaden retail reach and support top-line growth.
Bears Say
Legislative RiskAnalyst warns that H.R. 5371 could materially disrupt sales of certain THC-containing SKUs, including Herbal Oasis THC seltzers, creating significant uncertainty for revenue from those products.
LiquidityAnalyst flags a constrained cash position, noting limited liquidity could pressure operations even with access to a committed credit line that extends the financial runway temporarily.
cbdMD News
YCBD FAQ
What was cbdMD’s price range in the past 12 months?
cbdMD lowest stock price was $0.47 and its highest was $2.56 in the past 12 months.
What is cbdMD’s market cap?
cbdMD’s market cap is $7.20M.
When is cbdMD’s upcoming earnings report date?
cbdMD’s upcoming earnings report date is Aug 19, 2026 which is in 65 days.
How were cbdMD’s earnings last quarter?
cbdMD released its earnings results on May 14, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.03.
Is cbdMD overvalued?
According to Wall Street analysts cbdMD’s price is currently Undervalued.
Does cbdMD pay dividends?
cbdMD does not currently pay dividends.
What is cbdMD’s EPS estimate?
cbdMD’s EPS estimate is -0.03.
How many shares outstanding does cbdMD have?
cbdMD has 10,497,919 shares outstanding.
What happened to cbdMD’s price movement after its last earnings report?
cbdMD reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -5.309%.
Which hedge fund is a major shareholder of cbdMD?
Currently, no hedge funds are holding shares in YCBD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
cbdMD
cbdMD, Inc. is engaged in the production and distribution of a diverse array of cannabidiol (CBD) products. The company oversees and markets several consumer-oriented, hemp-derived CBD brands, notably its primary brand cbdMD, alongside Paw CBD and cbdMD Botanicals. Under the cbdMD label, its offerings span various items, including CBD tinctures, edible gummies, topical applications, capsules, bath bombs, bath salts, and solutions designed to aid sleep. Furthermore, its Paw CBD brand caters to pets with veterinarian-formulated products such as tinctures, edible chews, and topical treatments. The company's merchandise reaches customers throughout the United States via its proprietary e-commerce platform, various third-party online retail sites, wholesale partners, and physical brick-and-mortar establishments. cbdMD, Inc. also maintains a research collaboration with the University of Mississippi, focusing on the discovery of novel cannabinoids. Incorporated in 2015, the firm was previously known as Level Brands, Inc. before officially changing its name to cbdMD, Inc. in May 2019, and its corporate headquarters are situated in Charlotte, North Carolina.
YCBD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear operational progress: sequential and year-over-year revenue growth, strong wholesale expansion, positive early momentum from the Bluebird acquisition, improved per-share results, and proactive investments to pursue a new CMS BEI medical channel. Offsetting these positives are near-term margin compression, acquisition and strategic investment costs that produced operating and EBITDA losses, cash burn driven by working capital builds, and ongoing state-level regulatory volatility that raises compliance costs and market uncertainty. Management communicated plans and tools to improve margins and liquidity and expects Bluebird to be accretive in Q3 and the CMS opportunity to develop over 12–18 months.View all YCBD earnings summariesYCBD Stock 12 Month Forecast
Average Price Target
$2.00
▲(122.97% Upside)
Technical Analysis
Ownership Overview
15.05% Insiders
0.50% Mutual Funds
4.50% Other Institutional Investors
78.82% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---